Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients. We recently opened three new studies:

Diabetic Macular Edema
AVD-104-C301 (Dallas Main) — A Phase II study to evaluate the effect of intravitreal AVD-104 in participants with diabetic macular edema.

Diabetic Macular Edema and Wet Age-related Macular Degeneration (AMD)
Amarone EYE103-101 (Dallas Main, Plano) — A two-part study of intravitreal EYE103 in a mixed population of participants with diabetic macular edema and neovascular age-related macular degeneration (AMD)

Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)
IGS01 (Plano) — A natural history study evaluating biomarkers in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

In all, we currently have 30 open studies, offering access to promising new treatments for choroidal melanoma, diabetic macular edema, diabetic retinopathy, dry macular degeneration with geographic atrophy, retinal vein occlusion, wet macular degeneration, and uveitis.

Click here to view all our current, actively enrolling clinical trials.

For more information or to determine your eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.